Quantcast

DecisionQ Partners With Thomas Jefferson University to Reveal Insights for Cancer Therapy

April 29, 2009

Partnership integral piece of consortium recently awarded five-year, $6.7 million Susan G. Komen for the Cure Promise Grant

WASHINGTON, April 29 /PRNewswire/ — Thomas Jefferson University’s Kimmel Cancer Center has partnered with DecisionQ, a leader in predictive analytics and machine learning to uncover life-saving answers hidden in the center’s proprietary and extensive cancer registries. DecisionQ will leverage its expertise in developing predictive algorithms to identify how patients will respond to different therapeutic options for breast and colon cancers.

The team is part of a consortium that was recently awarded a Susan G. Komen for the Cure Promise Grant of nearly $6.7 million for five years of continued breast cancer research. Promise grants support multi-disciplinary research with the greatest potential to significantly reduce breast cancer incidence and/or mortality within the next decade.

“Identification of therapy-relevant biomarkers is a crucial part of breast cancer research, as there are many different biomarkers that could predict treatment response and outcome, and serve as targets for treatment,” said Hallgeir Rui, M.D., Ph.D., professor of Cancer Biology at Thomas Jefferson University. “DecisionQ’s Faster AnalyticsTM will be used to further refine the team’s predictive models in breast cancer, helping us to identify protein biomarker patterns that can be used to make sure patients are offered the most appropriate therapy.”

Leading experts in the fields of decision analysis, statistics and machine learning have developed the technology and approach that DecisionQ applies in creating MMIA’s (multi marker interpretive assays), greatly enhancing the quality of human judgment in an interactive, real-time environment at a low marginal cost.

“More than a million new cancer diagnoses are documented each year, giving researchers vast amounts of data with which to work,” said Todd Radano, co-founder of DecisionQ. “Applying advances in analytics via machine learning will assist scientists in taking what is known about the disease and developing actionable insights that could ultimately save lives.”

About DecisionQ Corporation

DecisionQ is a leader in predictive analytics and machine learning technologies with expertise in the healthcare, life sciences, financial services and security industries. Through the application of its advanced technologies and methods it delivers customers substantial improvements in the speed and quality of decision making by allowing them to quickly turn data into actionable insights. To learn more about DecisionQ visit www.decisionq.com.

                                         Contact:
                                         Laura Phillips, Vehr Communications
                                         513.381.8347
                                         lphillips@vehrcommunications.com

SOURCE DecisionQ Corporation


Source: newswire



comments powered by Disqus